Generics
Interchange of Narrow Therapeutic Index (NTI) Drugs 11/01/1999 Introduced | AMCP supports the Food and Drug Administration's (FDA) position that when an FDA-approved and therapeutically equivalent generic drug is selected, patients, physicians, and pharmacists can be assured that they will see the same clinical results and safety profile as with the equivalent brand name product. Therefore, NTI drugs should not be considered as a separate category for purposes of generic substitution. AMCP believes that pharmacists, in consultation with prescribers, should have the right to use their professional judgment and knowledge of the available scientific information in determining when to substitute a generic product. |
Featured News & Resources
See Full CalendarUpcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
